Supplements

← vista completa

Published on December 1, 2010 | http://doi.org/10.5867/medwave.2010.11.4812

Evidence Exforge D

Evidencia Exforge D

Luis Alcocer

This work is licensed under a Creative Commons Attribution 4.0 International License. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Authors

Luis Alcocer

Hospital General de México, Universidad Nacional Autónoma de México.

Figures

Article has no figures.

Forum

No messages

History

Citation Alcocer L. Evidence Exforge D. Medwave 2010;10(11):e4812 doi: 10.5867/medwave.2010.11.4812

Submission date 01/01/1970

Acceptance date 01/01/1970

Publication date 01/12/2010

Index

Metrics

Not available at the moment.

Notes

References

  1. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs. 2002;62(3):443-62. | CrossRef | PubMed
  2. Bakris GL. The importance of blood pressure control in the patient with diabetes. Am J Med. 2004 Mar 8;116 Suppl 5A:30S-38S. | CrossRef | PubMed
  3. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005 Sep 10-16;366(9489):895-906. | CrossRef | PubMed
  4. Calhoun DA, Lacourcière Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension. 2009 Jul;54(1):32-9. Epub 2009 May 26. | CrossRef | PubMed
  5. Flack JM, Calhoun DA, Satlin L, Barbier M, Hilkert R, Brunel P. Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study. J Hum Hypertens. 2009 Jul;23(7):479-89. Epub 2009 Jan 29. | CrossRef | PubMed
  6. Beevers G, Lip GY, O'Brien E. ABC of hypertension: The pathophysiology of hypertension. BMJ. 2001 Apr 14;322(7291):912-6. | CrossRef | PubMed
  7. Izzo JL, Jr. The sympathetic nervous system in acute and chronic blood pressure elevation. In: Oparil S, Weber MA, editors. Hypertension: Companion to Brenner & Rector’s The Kidney. 2nd ed. Philadelphia: Elsevier Saunders, 2005. p. 60-76.
  8. Smith TR, Philipp T, Vaisse B, Bakris GL, Wernsing M, Yen J, Glazer R. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of 2 randomized, placebo-controlled studies. J Clin Hypertens (Greenwich). 2007 May;9(5):355-64. | CrossRef | PubMed
  9. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009 May 19;338:b1665. | CrossRef | PubMed